Drug–drug interactions involving antidepressants: focus on desvenlafaxine

References

• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders5th edArlington (VA)APA2013
   Google Scholar
• World Health OrganizationDepression2017 Available from: http://www.who.int/mediacentre/factsheets/fs369/enAccessed May 30, 2017
   Google Scholar
• KangHJKimSYBaeKYComorbidity of depression with physical disorders: research and clinical implicationsChonnam Med J201551181825914875
   PubMedGoogle Scholar
• National Institute for Health and Care ExcellenceDepression in Adults with a Chronic Physical Health Problem: Recognition and ManagementLondonNICE2009
   Google Scholar
• KesslerRCBirnbaumHGShahlyVAge differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey InitiativeDepress Anxiety201027435136420037917
   PubMed Web of Science ®Google Scholar
• RodriguesMCde OliveiraCDrug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative reviewRev Lat Am Enfermagem201624e280027598380
   PubMed Web of Science ®Google Scholar
• PalleriaCDi PaoloAGiofrèCPharmacokinetic drug-drug interaction and their implication in clinical managementJ Res Med Sci201318760161024516494
   PubMed Web of Science ®Google Scholar
• KennedyCBrewerLWilliamsDDrug interactionsMedicine2016447422426
   Google Scholar
• ZangerUMRaimundoSEichelbaumMCytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistryNaunyn Schmiedebergs Arch Pharmacol20043691233714618296
   PubMed Web of Science ®Google Scholar
• ScheenAJCytochrome P450-mediated cardiovascular drug interactionsExpert Opin Drug Metab Toxicol2011791065108221810031
   PubMed Web of Science ®Google Scholar
• MulderHHeerdinkERvan IerselEEWilminkFWEgbertsACPrevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional studyAnn Pharmacother200741340841317341534
   PubMed Web of Science ®Google Scholar
• PreskornSHNicholsAIPaulJPatronevaALHelznerECGuico-PabiaCJEffect of desvenlafaxine on the cytochrome P450 2D6 enzyme systemJ Psychiatr Pract200814636837819057238
   PubMed Web of Science ®Google Scholar
• PreskornSHKaneCPLobelloKCytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicineJ Clin Psychiatry201374661462123541126
   PubMed Web of Science ®Google Scholar
• ManolopoulosVGRagiaGAlevizopoulosGPharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomicsDrug Metabol Drug Interact2012271193122718622
   PubMedGoogle Scholar
• MartinJLeeKCPharmacogenomics of antidepressants for major depressive disorderMent Health Clin201219222224
   Google Scholar
• EnglishBADortchMEreshefskyLJheeSClinically significant psychotropic drug-drug interactions in the primary care settingCurr Psychiatry Rep201214437639022707017
   PubMed Web of Science ®Google Scholar
• PreskornSHFlockhartDThe Black Book of Psychiatric Drug InteractionsNew YorkMBL Communications2010
   Google Scholar
• Pristiq (desvenlafaxine) extended release tablets [prescribing information]SingaporePfizer2016
   Google Scholar
• CarrascoJLKornsteinSGMcIntyreRSAn integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorderInt Clin Psychopharmacol201631313414626895080
   PubMed Web of Science ®Google Scholar
• GuptaBMZargarSHAroraMTandonVREfficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: a preliminary 1-year prospective randomized open label comparative trialPerspect Clin Res201671455026955576
   PubMedGoogle Scholar
• SoaresCNThaseMEClaytonADesvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorderMenopause201017470071120539246
   PubMed Web of Science ®Google Scholar
• SoaresCNThaseMEClaytonAOpen-label treatment with des-venlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopramCNS Drugs201125322723821323394
   PubMed Web of Science ®Google Scholar
• GelenbergAFreemanMMarkowitzJCPractice Guideline for the Treatment of Patients with Major Depressive Disorder3rd edArlington (VA)American Psychiatric Association2010
   Google Scholar
• KennedySHLamRWMcIntyreRSCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder – section 3: pharmacological treatmentsCan J Psychiatry201661954056027486148
   PubMed Web of Science ®Google Scholar
• LamRWKennedySHGrigoriadisSCanadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults – III: pharmacotherapyJ Affect Disord2009117Suppl 1S26S4319674794
   PubMed Web of Science ®Google Scholar
• MalhiGSBassettDBoycePRoyal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disordersAust N Z J Psychiatry20154912118525870440
   PubMed Web of Science ®Google Scholar
• SangkuhlKStinglJCTurpeinenMAltmanRBKleinTEPharmGKB summary: venlafaxine pathwayPharmacogenet Genomics2014241627224128936
   PubMed Web of Science ®Google Scholar
• DeMaioWKaneCPNicholsAIJordanRMetabolism studies of desvenlafaxineJ Bioequiv Availab20113151160
   Google Scholar
• MacalusoMNicholsAIPreskornSHHow the probability and potential clinical significance of pharmacokinetically mediated drug-drug interactions are assessed in drug development: desvenlafaxine as an examplePrim Care Companion CNS Disord201517210.4088/PCC.4014r01710
   Google Scholar
• CongiuMMashfordMLSlavinJLDesmondPVUDP glucuronosyltransferase mRNA levels in human liver diseaseDrug Metab Dispos200230212913411792680
   PubMed Web of Science ®Google Scholar
• Baird-BellaireSBehrleJAParkerVDPatatAPaulJNicholsAIAn open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxineClin Ther201335678279423623756
   PubMed Web of Science ®Google Scholar
• NicholsAIRichardsLSBehrleJAPosenerJAMcGrorySBPaulJThe pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairmentInt J Clin Pharmacol Ther201149131321176719
   PubMed Web of Science ®Google Scholar
• FlockhartDADrug interactions: defining genetic influences on pharmacologic responses – cytochrome P450 drug interaction table2007 Available from: http://medicine.iupui.edu/clinpharm/ddisAccessed June 7, 2017
   Google Scholar
• SpinaEPisaniFde LeonJClinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychoticsPharmacol Res2016106728626896788
   PubMed Web of Science ®Google Scholar
• DumbreckSFlynnANairnMDrug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelinesBMJ2015350h94925762567
   PubMed Web of Science ®Google Scholar
• LugtenbergMBurgersJSClancyCWestertGPSchneiderECCurrent guidelines have limited applicability to patients with comorbid conditions: a systematic analysis of evidence-based guidelinesPLoS One2011610e2598722028802
   PubMed Web of Science ®Google Scholar
• LamRWKennedySHSareenJYathamLNWhy are there no treatment guidelines for mood disorders and comorbidities?Ann Clin Psychiatry20122414522303518
   PubMed Web of Science ®Google Scholar
• GlassmanAHDepression and cardiovascular comorbidityDialogues Clin Neurosci20079191717506222
   PubMedGoogle Scholar
• FlockhartDATanus-SantosJEImplications of cytochrome P450 interactions when prescribing medication for hypertensionArch Intern Med2002162440541211863472
   PubMed Web of Science ®Google Scholar
• BaharMAHakEBosJHBorgsteedeSDWilffertBThe burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderlyPharmacoepidemiol Drug Saf201726775276528345306
   PubMed Web of Science ®Google Scholar
• TrujilloTCNolanPEAntiarrhythmic agents: drug interactions of clinical significanceDrug Saf200023650953211144659
   PubMed Web of Science ®Google Scholar
• HolbrookAMPereiraJALabirisRSystematic overview of warfarin and its drug and food interactionsArch Intern Med2005165101095110615911722
   PubMed Web of Science ®Google Scholar
• DongYHBykovKChoudhryNKClinical outcomes of concomitant use of warfarin and selective serotonin reuptake inhibitors: a multidatabase observational cohort studyJ Clin Psychopharmacol201737220020928129313
   PubMed Web of Science ®Google Scholar
• WalengaJMAdiguzelCDrug and dietary interactions of the new and emerging oral anticoagulantsInt J Clin Pract201064795696720584229
   PubMed Web of Science ®Google Scholar
• DerijksHJHeerdinkERDe KoningFHJanknegtRKlungelOHEgbertsACThe association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control studyPharmacoepidemiol Drug Saf200817433634418302302
   PubMed Web of Science ®Google Scholar
• MoultonCDPickupJCIsmailKThe link between depression and diabetes: the search for shared mechanismsLancet Diabetes Endocrinol20153646147125995124
   PubMed Web of Science ®Google Scholar
• MadsenHEnggaardTPHansenLLKlitgaardNABrosenKFluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamideClin Pharmacol Ther2001691414711180037
   PubMed Web of Science ®Google Scholar
• TirkkonenTHeikkilaPHuupponenRLaineKPotential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizideJ Intern Med2010268435936620698928
   PubMed Web of Science ®Google Scholar
• GuthrieBPayneKAldersonPMcMurdoMEMercerSWAdapting clinical guidelines to take account of multimorbidityBMJ2012345e634123036829
   PubMed Web of Science ®Google Scholar
• KanagaratnamLMahmoudiRNovellaJLJollyDDraméMTrenqueTAdverse drug reactions in elderly subjects hospitalized in a specialized dementia management unitDrugs Aging2014311076977625200414
   PubMed Web of Science ®Google Scholar
• PasqualettiGTogniniSCalsolaroVPoliniAMonzaniFPotential drug–drug interactions in Alzheimer patients with behavioral symptomsClin Interv Aging2015101457146626392756
   PubMed Web of Science ®Google Scholar
• KornhuberJKennepohlEMBleichSMemantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approachClin Pharmacokinet200746759961217596105
   PubMed Web of Science ®Google Scholar
• TrivediMHKurianBTManaging depressive disorders in patients with epilepsyPsychiatry (Edgmont)2007412634
   PubMedGoogle Scholar
• Tellez-ZentenoJFPattenSBJetteNWilliamsJWiebeSPsychiatric comorbidity in epilepsy: a population-based analysisEpilepsia200748122336234417662062
   PubMed Web of Science ®Google Scholar
• de LeonJThe effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue – part I: a summary of the current state for cliniciansRev Psiquiatr Salud Ment2015829711525745819
   PubMed Web of Science ®Google Scholar
• LandmarkCJPatsalosPNDrug interactions involving the new second-and third-generation antiepileptic drugsExpert Rev Neurother201010111914020021326
   PubMed Web of Science ®Google Scholar
• RamasubbuRTaylorVHSamaanZThe Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditionsAnn Clin Psychiatry20122419110922303525
   PubMed Web of Science ®Google Scholar
• JetteNPattenSWilliamsJBeckerWWiebeSComorbidity of migraine and psychiatric disorders: a national population-based studyHeadache200848450151618070059
   PubMed Web of Science ®Google Scholar
• KalaydjianAMerikangasKPhysical and mental comorbidity of headache in a nationally representative sample of U.S. adultsPsychosom Med200870777378018725426
   PubMed Web of Science ®Google Scholar
• NapoletanoFLionettoLMartellettiPSumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidityExpert Opin Pharmacother201415330330524206090
   PubMed Web of Science ®Google Scholar
• RolanPEDrug interactions with triptansCNS Drugs2012261194995723018546
   PubMed Web of Science ®Google Scholar
• TepperSAllenCSandersDGreeneABoccuzziSCoprescription of triptans with potentially interacting medications: a cohort study involving 240 268 patientsHeadache2003431444812864757
   PubMed Web of Science ®Google Scholar
• AnsariHKoutiLDrug interaction and serotonin toxicity with opioid use: another reason to avoid opioids in headache and migraine treatmentCurr Pain Headache Rep20162085027457368
   PubMed Web of Science ®Google Scholar
• EvansRWTepperSJShapiroRESun-EdelsteinCTietjenGEThe FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin- norepinephrine reuptake inhibitors: American Headache Society position paperHeadache20105061089109920618823
   PubMed Web of Science ®Google Scholar
• KogutSJDo triptan antimigraine medications interact with SSRI/SNRI antidepressants? What does your decision support system say?J Manag Care Pharm201117754755121870895
   PubMed Web of Science ®Google Scholar
• Imigran (sumatriptan) film-coated tablet [prescribing information]SingaporeGlaxoSmithKline2015
   Google Scholar
• EvansRWThe FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reportsMedGenMed20079348
   PubMedGoogle Scholar
• SpinaEde LeonJClinically relevant interactions between newer antidepressants and second-generation antipsychoticsExpert Opin Drug Metab Toxicol201410572174624494611
   PubMed Web of Science ®Google Scholar
• SpinaEde LeonJMetabolic drug interactions with newer antipsychotics: a comparative reviewBasic Clin Pharmacol Toxicol2007100142217214606
   PubMed Web of Science ®Google Scholar
• BorkJARogersTWedlundPJde LeonJA pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3AJ Clin Psychiatry199960746947610453802
   PubMed Web of Science ®Google Scholar
• AvenosoAFacciolàGScordoMGNo effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophreniaClin Drug Investig1998165393398
   Web of Science ®Google Scholar
• UrichukLPriorTIDursunSBakerGMetabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactionsCurr Drug Metab20089541041818537577
   PubMed Web of Science ®Google Scholar
• BoultonDWBalchAHRoyzmanKThe pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorderJ Psychopharmacol201024453754618832427
   PubMed Web of Science ®Google Scholar
• ChibandaDDepression and HIV: integrated care towards 90–90–90Int Health201792777928115469
   PubMed Web of Science ®Google Scholar
• TaoJVermundSHQianHZAssociation between depression and antiretroviral therapy use among people living with HIV: a meta-analysisAIDS Behav Epub2017424
   Web of Science ®Google Scholar
• DeSilvaKELe FloreDBMarstonBJRimlandDSerotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetineAIDS200115101281128511426073
   PubMed Web of Science ®Google Scholar
• HillLLeeKCPharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychoticsAnn Pharmacother2013471758923341158
   PubMed Web of Science ®Google Scholar
• Norvir (ritonavir) film-coated tablet [prescribing information]SingaporeAbbVie2016
   Google Scholar
• GutierrezMMRosenbergJAbramowitzWAn evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavirClin Ther20032541200121012809966
   PubMed Web of Science ®Google Scholar
• Crixivan (indinavir) capsules [prescribing information]SingaporeMSD Pharma2012
   Google Scholar
• JannMWSpratlinVMomaryKLack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavirEur J Clin Pharmacol201268571572122173281
   PubMed Web of Science ®Google Scholar
• de MaatMMHuitemaADMulderJWDrug interaction of fluvoxamine and fluoxetine with nevirapine in HIV-1-infected individualsClin Drug Investig20032310629637
   PubMed Web of Science ®Google Scholar
• PattenSBBeckCAKassamAWilliamsJVBarbuiCMetzLMLong-term medical conditions and major depression: strength of association for specific conditions in the general populationCan J Psychiatry200550419520215898458
   PubMed Web of Science ®Google Scholar
• SiebenhuenerKEschmannEKienastAChronic pain: how challenging are DDIs in the analgesic treatment of inpatients with multiple chronic conditions?PloS One2017121e016898728046033
   PubMed Web of Science ®Google Scholar
• Durogesic (fentanyl) transdermal patch [prescribing information]SingaporeJohnson & Johnson2017
   Google Scholar
• LotschJSkarkeCTegederIGeisslingerGDrug interactions with patient-controlled analgesiaClin Pharmacokinet20024113157
   PubMed Web of Science ®Google Scholar
• PergolizziJVJrMaLFosterDRThe prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patientsJ Manag Care Spec Pharm201420546747624761818
   PubMed Web of Science ®Google Scholar
• Durotram (tramadol hydrochloride) extended release tablets [prescribing information]SingaporeInova Pharmaceuticals2015
   Google Scholar
• GnanadesiganNEspinozaRTSmithRIsraelMReubenDBInteraction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected?J Am Med Dir Assoc20056426526916005413
   PubMedGoogle Scholar
• GrondSSablotzkiAClinical pharmacology of tramadolClin Pharmacokinet2004431387992315509185
   PubMed Web of Science ®Google Scholar
• SolomonDHNSAIDs: therapeutic use and variability of response in adults2017 Available from: https://www.uptodate.com/contents/nsaids-therapeutic-use-and-variability-of-response-in-adultsAccessed June 13, 2017
   Google Scholar
• Arcoxia (etoricoxib) film-coated tablets [prescribing information]SingaporeMSD Pharma2015
   Google Scholar
• Celebrex (celecoxib) capsules [prescribing information]SingaporePfizer2016
   Google Scholar
• Nurofen (Ibuprofen) sugar-coated tablet [prescribing information]SingaporeReckitt Benckiser2015
   Google Scholar
• Voltaren (diclofenac) film-coated tablet [prescribing information]SingaporeNovartis2016
   Google Scholar
• Aleve (naproxen) film-coated tablet [prescribing information]SingaporeBayer2015
   Google Scholar
• MeijerWEHeerdinkERNolenWAHeringsRMLeufkensHGEgbertsACAssociation of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressantsArch Intern Med2004164212367237015557417
   PubMedGoogle Scholar
• ChengYLHuHYLinXHUse of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in TaiwanMedicine (Baltimore)20159446e202226579809
   PubMed Web of Science ®Google Scholar
• de AbajoFJGarcia-RodriguezLARisk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agentsArch Gen Psychiatry200865779580318606952
   PubMed Web of Science ®Google Scholar
• WeinsteinAAKallman PriceJStepanovaMDepression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and CPsychosomatics201152212713221397104
   PubMed Web of Science ®Google Scholar
• SchaeferMCapuronLFriebeAHepatitis C infection, antiviral treatment and mental health: a European expert consensus statementJ Hepatol20125761379139022878466
   PubMed Web of Science ®Google Scholar
• CartaMGHardoyMCGarofaloAAssociation of chronic hepatitis C with major depressive disorders: irrespective of interferon-α therapyClin Pract Epidemiol Ment Health200732217956625
   PubMedGoogle Scholar
• Pegasys (PEG-interferon α2a) subcutaneous injection [prescribing information]SingaporeRoche2017
   Google Scholar
• SmoldersEJde KanterCTde KnegtRJvan der ValkMDrenthJPBurgerDMDrug–drug interactions between direct-acting antivirals and psychoactive medicationsClin Pharmacokinet201655121471149427317413
   PubMed Web of Science ®Google Scholar
• Victrelis (boceprevir) capsule [prescribing information]SingaporeMSD Pharma2017
   Google Scholar
• SockalingamSTsengAGiguerePWongDPsychiatric treatment considerations with direct acting antivirals in hepatitis CBMC Gastroenterol2013138623672254
   PubMed Web of Science ®Google Scholar
• NgCGBoksMPMZainalNZde WitNJThe prevalence and pharmacotherapy of depression in cancer patientsJ Affect Disord20111311–31720732716
   PubMed Web of Science ®Google Scholar
• ChanAYapKYKohDLowXHCheungYTElectronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to cliniciansPharmacoepidemiol Drug Saf201120993994721732473
   PubMed Web of Science ®Google Scholar
• ChanANgTRYapKYClinically-relevant anticancer-antidepressant drug interactionsExpert Opin Drug Metab Toxicol20128217319922191471
   PubMed Web of Science ®Google Scholar
• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• BlowerPde WitRGoodinSAaproMDrug-drug interactions in oncology: why are they important and can they be minimized?Crit Rev Oncol Hematol200555211714215890526
   PubMed Web of Science ®Google Scholar
• BeijnenJHSchellensJHMDrug interactions in oncologyLancet Oncol20045848949615288238
   PubMed Web of Science ®Google Scholar
• EngelsFKTen TijeAJBakerSDEffect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelClin Pharmacol Ther200475544845415116057
   PubMed Web of Science ®Google Scholar
• NicholsALiangYMatschkeKAn evaluation of the potential of cytochrome P450 3A4-mediated drug-drug interactions with desvenlafaxine useJ Bioequiv Availab201355359
   Google Scholar
• Tarceva (erlotinib) film-coated tablet [prescribing information]SingaporeRoche2016
   Google Scholar
• Iressa (gefitinib) film-coated tablet [prescribing information]SingaporeAstraZeneca2017
   Google Scholar
• YapKYTayWLChuiWKChanAClinically relevant drug interactions between anticancer drugs and psychotropic agentsEur J Cancer Care2011201632
   PubMed Web of Science ®Google Scholar
• Glivec (imatinib) film-coated tablet [prescribing information]SingaporeNovartis2016
   Google Scholar
• BoddyAVYuleSMMetabolism and pharmacokinetics of oxazaphosphorinesClin Pharmacokinet200038429130410803453
   PubMed Web of Science ®Google Scholar
• Adriamycin (doxorubicin) intravenous injection [prescribing information]SingaporePfizer2015
   Google Scholar
• CaraciFCrupiRDragoFSpinaEMetabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and Hypericum extractCurr Drug Metab201112657057721395523
   PubMed Web of Science ®Google Scholar
• ColleoniMGelberSGoldhirschATamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93J Clin Oncol20062491332134116505417
   PubMed Web of Science ®Google Scholar
• KellyCMJuurlinkDNGomesTSelective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort studyBMJ2010340c69320142325
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyCHMP Pharmacovigilance Working Party (PhVWP): September 2010 plenary meeting2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097444.pdfAccessed July 27, 2017
   Google Scholar
• NicholsAILubaczewskiSLiangYMatschkeKBraleyGRameyTOpen-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjectsInt J Clin Pharmacol Ther2014521083084125138680
   PubMed Web of Science ®Google Scholar
• Campto (irinotecan) intravenous injection [prescribing information]SingaporePfizer2014
   Google Scholar
• RichardsSUmbreitJNFanucchiMPGiblinJKhuriFSelective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecanSouth Med J200396101031103314570350
   PubMed Web of Science ®Google Scholar
• Sunvepra (asunaprevir) capsule [prescribing information]SingaporeBristol-Myers Squibb2016
   Google Scholar
• Olysio (simprevir) capsule [prescribing information]SingaporeJohnson & Johnson2017
   Google Scholar